Indian Patent Office

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics

by

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go far enough.   Delhi/Cape Town/Geneva, 18 July, 2023 – As Johnson & Johnson’s (J&J) 20-year … Read more

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

by

Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes two patent oppositions filed by Delhi Network of Positive People (DNP+) before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These oppositions challenge Gilead’s patent applications for the tablet formulation of the fixed-dose combination of … Read more

Indian patent office delivers major blow to affordable pneumonia vaccine hopes

by

Geneva/New York/New Delhi, 22 August 2017 – Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that safeguards both children and adults from pneumonia were dealt a major blow after the Indian patent office granted a patent to the US pharmaceutical corporation Pfizer for its PCV13 product, marketed as Prevnar13. “It’s unfair and … Read more